Streetwise Articles

Biotech Delivers Positive Study Results for Prostate Cancer Prognostic Test
Source: Streetwise Reports  (12/5/18)
An H.C. Wainwright & Co. report reviewed this firm's latest news concerning a data readout, trial approval and therapeutic application. More >

Precision Medicine Developer Secures Another Patent for Drug Candidate
Source: Streetwise Reports  (12/5/18)
This company takes a step forward in its efforts to protect its intellectual property. More >

Biotech to Lead dMAB Tech Field with First Clinically Tested Product
Source: Streetwise Reports  (11/28/18)
An H.C. Wainwright & Co. report discussed recent articles covering results of this firm's preclinical studies. More >

Neuromonitoring Stock 'Ready to Rally'
Source: Clive Maund for Streetwise Reports  (11/26/18)
Technical analyst Clive Maund charts a neuromonitoring company that he believes is undervalued. More >

Cannabis Provider to Debut Five More Dispensaries in Florida
Source: Streetwise Reports  (11/26/18)
This company plans to add even more this year as well. More >

Biopharma Agrees to $215 Million Acquisition Deal
Source: Streetwise Reports  (11/21/18)
An H.C. Wainwright & Co. report detailed the terms of the definitive agreement concerning the merger. More >

Biopharma to Accelerate Trial Timeline with Amendment
Source: Streetwise Reports  (11/21/18)
The change relates to the onset of dosing for patients with different degrees of disease. More >

Biotech Ramps Up Philippine Sales of Livestock Feed Premix
Source: Streetwise Reports  (11/21/18)
A distributor of the proprietary product places a third large order. More >

Life Science Company Addresses Antibiotic Resistance Problem
Source: Streetwise Reports  (11/18/18)
This firm's proprietary technology provides an alternative to antibiotic use in livestock production. More >

Biotech Files Patent Application for Nitric Oxide Delivery Device
Source: Streetwise Reports  (11/16/18)
With this development, the company advances blood/plasma transfusion technology.
More >

Daniel Carlson

Imprimis: Priming the Pumps for a Big 2019
Source: Daniel Carlson for Streetwise Reports  (11/15/18)
Daniel Carlson of Tailwinds Research profiles a biotech company he is bullish on. More >

Catalysts Approaching for U.S. Developer of Cancer Therapeutics
Source: Streetwise Reports  (11/10/18)
An H.C. Wainwright & Co. report highlighted this biotech's upcoming key events to watch. More >

Biotech Announces Preclinical Data on its Intravaginal Rings at Meeting
Source: Streetwise Reports  (11/10/18)
A ROTH Capital Partners report relayed the contents of both presented abstracts. More >

Target Price Raised on Biotech in Anticipation of Clinical Trial Presentation
Source: Streetwise Reports  (11/7/18)
An H.C. Wainwright & Co. report discussed what investors might expect to hear from the company regarding its cholesterol-lowering therapy. More >

Coverage Initiated on Developer of Targeted Gene Therapies for Cancer
Source: Streetwise Reports  (11/7/18)
A LifeSci Capital report highlighted the advantages of this biotech story's lead candidate targeting bladder cancer. More >

Selectively Targeting Alzheimer's Disease's Root Cause Is Key, Biotech Says
Source: Streetwise Reports  (11/7/18)
This firm explains how its 15 years in drug development led to and supports this conclusion. More >

Frederick Lacy

Hemp Sales Grow at CV Sciences: Q3 Beats Estimates, 2019 Outlook
Source: Fincom Investment Partners for Streetwise Reports  (11/7/18)
Fincom Investment Partners takes a look at Q3 earnings for a U.S.-based CBD company and explains why it believes it offers good value. More >

Ron Struthers

A Canadian Cannabis Company for the Next Wave
Source: Ron Struthers for Streetwise Reports  (11/6/18)
Ron Struthers, who believes the ideal marijuana stock to buy at this time is one that is focused on cannabis oil, profiles one such company that he sees as undervalued. More >

Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential'
Source: Streetwise Reports  (10/31/18)
A ROTH Capital Partners report outlines its reasons for initiating coverage on this epigenetic therapeutics developer, whose lead candidate is in trials in diabetes, end-stage renal disease and other indications. More >

Biotech Pinpoints Third Set of Targets for Potential Alzheimer's Treatment
Source: Streetwise Reports  (10/31/18)
With this achievement, the firm expands its potential partnering opportunities. More >

Steve Palmer

Three Small-Caps on This Fund Manager's List
Source: Streetwise Reports  (10/30/18)
Steve Palmer, founding partner, President and Chief Investment Officer of AlphaNorth Asset Management, talks with Streetwise Reports about several small-cap companies from three sectors that he has been following. More >

Update on Stock in Vanguard of Drive to Phase Out Antibiotics in Animal Feed
Source: Clive Maund for Streetwise Reports  (10/29/18)
Technical analyst Clive Maund provides an update on a company whose product is replacing antibiotics for growth promotion in animal feed. More >

This Biotech, Whose Discovery Could End Routine Antibiotic Use in Livestock, Is the Pick of Three Fund Managers
Source: Streetwise Reports  (10/27/18)
Multiple governments around the world have unleashed mandates on livestock feed regulations that pose an opportunity for a Canada-based biotech company. More >

Daniel Carlson

As Anixa Starts Approaching the FDA, We Discuss Its Two Innovative Programs
Source: Daniel Carlson for Streetwise Reports  (10/27/18)
Dr. Amit Kumar, CEO of Anixa Biosciences, sits down with Daniel Carlson of Tailwinds Research to discuss the company's trials of CAR-T for solid tumors, as well as its Cchek program to distinguish between benign conditions and malignant cancer. More >

Daniel Carlson

Catasys…Future's So Bright
Source: Daniel Carlson for Streetwise Reports  (10/27/18)
Daniel Carlson of Tailwinds Research discusses a company that helps health plans solve the hidden, high-cost problem of untreated behavioral health conditions. More >

Showing Results: 1 to 25 of 977 Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts